Risk factors in neuroleptic malignant syndrome. A case-control study

Acta Psychiatrica Scandinavica

Volumn 107, Issue 1, 2003, Pages 45-49

  Viejo, Luis Fernando ^a   Morales, V ^a   Punal P ^a   Perez J L ^a   Sancho, R A ^a  

^a HOSPITAL VIRGEN DE LA SALUD   (Spain)

Author keywords

Dose response relationship; Drug; Mental retardation; Neuroleptic malignant syndrome; Psychomotor agitation; Risk factors

Indexed keywords

CHLORPROMAZINE; CLOTIAPINE; CLOZAPINE; FLUPHENAZINE DECANOATE; HALOPERIDOL; NEUROLEPTIC AGENT; PIMOZIDE; RISPERIDONE; THIORIDAZINE; TIAPRIDE;

ADULT; AGITATION; ARTICLE; CASE CONTROL STUDY; CLINICAL ARTICLE; CONTROLLED STUDY; DOSE RESPONSE; ENVIRONMENTAL TEMPERATURE; FEMALE; HUMAN; MALE; MENTAL DEFICIENCY; MOOD DISORDER; MULTIVARIATE ANALYSIS; NEUROLEPTIC MALIGNANT SYNDROME; PRIORITY JOURNAL; RESTLESSNESS; RISK FACTOR; STATISTICAL SIGNIFICANCE; TEMPERATURE;

ADULT; ANTIPSYCHOTIC AGENTS; CASE-CONTROL STUDIES; ENVIRONMENT; FEMALE; HUMANS; MALE; MENTAL RETARDATION; MOOD DISORDERS; NEUROLEPTIC MALIGNANT SYNDROME; PSYCHOMOTOR AGITATION; RISK FACTORS; TEMPERATURE;

EID: 12244268607     PISSN: 0001690X     EISSN: None     Source Type: Journal    
DOI: 10.1034/j.1600-0447.2003.02385.x     Document Type: Article

References (28)

1. CAROFF SN. The neuroleptic malignant syndrome. J Clin Psychiatry 1980;41:79-83.
2. GELENBERG AJ, BELLINGHAUSEN B, WOJCIK JD, FALK WE, SACHS GS. A prospective survey of neuroleptic malignant syndrome in a short-term psychiatric hospital. Am J Psychiatry 1988;145:517-518.
3. ADDONIZIO G, SUSMAN VL, ROTH SD. Symptoms of neuroleptic malignant syndrome in 82 consecutive inpatients. Am J Psychiatry 1986;143:1587-1590.
4. RIVERA J, GARCÍA-BRAGADO F. IRIARTE LM et al. Síndrome neuroléptico maligno. Análisis de 9 casos. Med Clin (Barc) 1990;94:121-125.
5. ROSEBUSH PI, STEWART T. A prospective analysis of 24 episodes of neuroleptic malignant syndrome. Am J Psychiatry 1989;146:717-725.
6. NAGANUMA H, FUJII I. Incidence and risk factors in neuroleptic malignant syndrome. Acta Psychiatr Scand 1994;90:424-426.
7. CAROFF SN, MANN SC. Neuroleptic malignant syndrome. Med Clin N Am 1993;77:185-202.
8. SHALEV A, MUNITZ H. The neuroleptic malignant syndrome. agent and host interaction. Acta Psychiatr Scand 1986;73:337-347.
9. KECK PE, POPE HG, MCELROY SL. Risk factors for neuroleptic malignant syndrome. A case-control study. Arch General Psychiatry 1989;46:914-918.
10. SACHDEV P, MASON C, HADZI-PAVLOVIC D. Case-control study of neuroleptic malignant syndrome. Am J Psychiatry 1997;154:1156-1158.
11. BERARDI D, AMORE M, KECK PE Jr, TROIA M, DELL'ATTI M. Clinical and pharmacologic factors for neuroleptic malignant syndrome. Biol Psychiatry 1998;44:748-754.
12. KECK PE, POPE HG, MCELROY SL. Declining frequency of neuroleptic malignant syndrome in a hospital population. Am J Psychiatry 1991;148:880-882.
13. DENG MZ, CHENG GQ, PHILLIPS MR. Neuroleptic malignant syndrome in 12 of 9729 Chinese inpatients exposed to neuroleptics: a prospective survey. Am J Psychiatry 1990;147:1149-1155.
14. DELAY J, PICHOT P, LEMPÉRIÈRE T, ELISSALDE B, PEIGNE F. Un neuroleptique majeur non phénothiazinique et non réserpinique, l'haloperidol, dans le traitement des psychoses. Ann Méd Psychol 1960;118:145-152.
15. POPE HG, KECK PE, MCELROY SL. Frequency and presentation of neuroleptic malignant syndrome in a large psychiatric hospital. Am J Psychiatry 1986;143:1227-1233.
16. KECK PE, POPE HG, MCELROY SL. Frequency and presentation of neuroleptic malignant syndrome: a prospective study. Am J Psychiatry 1987;144:1344-1346.
17. HERMESH H, AIZENBERG D, WEIZMAN A, LAPIDOT M, MAYOR C, MUNITZ H. Risk for definite neuroleptic malignant syndrome. A prospective study in 223 consecutive inpatients. Br J Psychiatry 1992;161:254-257.
18. SHALEV A, HERMESH H, MUNITZ H. The role of external heat load in triggering the neuroleptic malignant syndrome. Am J Psychiatry 1988;145:110-111.
19. LEVENSON JL. Neuroleptic malignant syndrome. Am J Psychiatry 1985;142:1137-1145.
20. DAVIS JM. Dose equivalence of the antipsychotic drugs. J Psychiat Res 1974;11:65-69.
21. DAVIS JM. Comparative doses and cost of antipsychotic medication. Arch Gen Psychiatry 1976;88:858-861.
22. BARCIA D, GALIANA M, LÓPEZ L. Neurolépticos. In: LÓPEZ-IBOR ALIÑO JJ, BARCIA SALORIO D, RUIZ OGARA C, eds. Psiquiatría. S.A. Barcelona: Ediciones Toray, 1982.
23. Guía Práctica de Psicofármacos Opioides y Drogas de Abuso. Madrid: Ed. Roche, 1995:82.
24. VIEJO LLORENTE LF. Sindrome Neuroléptico Maligno. Análisis y seguimiento de 21 episodios. PhD Thesis. Madrid Complutense University, School of Medicine, 1995.
25. STERNBERG DE. Neuroleptic malignant syndrome: the pendulum swings (Editorial). Am J Psychiatry 1986;143:1273-1275.
26. GURRERA RJ. Sympathoadrenal hyperactivity and the etiology of neuroleptic malignant syndrome. Am J Psychiatry 1999;156:169-180.
27. FITZGERALD B, MIDDLETON JK, COOPER SA. Adverse effects of summer amongst people with learning disabilities: neuroleptic malignant syndrome. J Intellect Disabil Res 1997;41:273-277.
28. TANII H, TANIGUCHI N, NIIGAWA H et al. Development of an animal model for neuroleptic malignant syndrome: heat-exposed rabbits with haloperidol and atropine administration exhibit increased muscle activity, hyperthermia, and high serum creatine phosphokinase level. Brain Res 1996;743:263-270.